TGTX Q2 2022 Earnings — TG Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TGTXTG Therapeutics, Inc.

$5B

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$594,000-61.6% YoY

Gross Profit

$571,00096.1% margin

Operating Income

-$39M-6555.7% margin

Net Income

-$41M-6819.9% margin

EPS (Diluted)

$-0.30

QoQ Revenue Growth

-70.5%

Cash Flow

Operating Cash Flow

-$49M

Free Cash Flow

-$49M

Stock-Based Comp.

-$975,000

Balance Sheet

Total Assets

$252M

Total Liabilities

$123M

Stockholders' Equity

$129M

Cash & Equivalents

$147M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$594,000	$2M	-61.6%
Gross Profit	$571,000	$1M	-59.1%
Operating Income	-$39M	-$77M	+49.7%
Net Income	-$41M	-$78M	+48.4%

Revenue Segments

Product revenue, net

$556,00094%

License revenue

$38,0006%